Trial Profile
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Jan 2022
Price :
$35
*
At a glance
- Drugs APTO 253 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors Aptose Biosciences
- 20 Dec 2021 Status changed from recruiting to discontinued because company decided to discontinue further clinical development of APTO-253. The decision follows prioritization of the company's other more advanced pipeline candidates, as well as an internal review of the product profile and performance to date of APTO-253, including a clinical hold placed by the U.S. Food & Drug Administration, according to an Aptose Biosciences.
- 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 13 Dec 2021 According to an Aptose Biosciences media release, the company will be holding a corporate update to discuss the data from this trial.